L
Power Law company profile
Loxo Oncology
Biotech & Life Sciences · York, United Kingdom · Founded 2013 · IPO 2014 Unicorn
Global footprint
Where Loxo Oncology has talent and traffic
AI talent share
0.4%
of workforce is AI talent
(1 of 257 staff)
(1 of 257 staff)
Core AI10.39%
Other AI00%
Non-AI workforce25699.61%
Web traffic by country
50
monthly visits
across markets
across markets
🇺🇸 United States3400%
🇮🇳 India400%
Patent intelligence
$130M patent portfolio · 45 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$130M
1.6% of valuation · 3.1× smaller than top peer Seagen ($403M)
45 active patent families
Where Loxo Oncology innovates
CarcinosisPyrazoleDiseaseMolecular biologyTyrosine
Above peer median on Strategic, Market
Quality vs same-sector peers
Loxo Oncology on the five Patsnap quality dimensions
Loxo Oncology in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Loxo Oncology concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Loxo Oncology and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Loxo Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.